SKB BIO (06990) climbed more than 4% before the midday trading session, with shares last up 3.8% to HK$510.5, on turnover of HK$95.924 million.

The company recently announced that it has received a clinical trial approval notice from the Center for Drug Evaluation of the National Medical Products Administration for its novel dual-load ADC drug candidate, SKB565, intended for the treatment of advanced solid tumors. This marks the first dual-load antibody-drug conjugate from SKB BIO to enter the clinical stage, with the approval of SKB565 representing a key step forward in the company's "ADC+IO" integrated development strategy.